


# EXHIBIT B

[Back to the Newsroom](#)

## Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders

Topic:

Class Action

Sunday, 29 December 2024 07:30 PM

**NEW YORK, NY / ACCESSWIRE / December 29, 2024 /** If you suffered a loss on your **Cassava Sciences, Inc.** (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

<https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119319&wire=1>

or contact Joseph E. Levi, Esq. via email at [jlevi@levikorsinsky.com](mailto:jlevi@levikorsinsky.com) or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

**THE LAWSUIT:** A class action securities lawsuit was filed against Cassava Sciences, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.

**CASE DETAILS:** According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included, among other things, clear confidence in simufilam's ability to treat Alzheimer's Disease. On November 25, 2024, Cassava released topline results for the first of its two ongoing Phase 3 studies on simufilam, the "ReThink-ALZ" study. The results indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo.

Following this news, the price of Cassava's common stock declined dramatically. From a closing market price of \$26.48 per share on November 22, 2024, Cassava's stock price fell to \$4.30 per share on November 25, 2024, a decline of about 83.76% in the span of just a single day.

**WHAT'S NEXT?** If you suffered a loss in Cassava Sciences, Inc. stock during the relevant time frame - even if you still hold your shares - go to <https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119319&wire=1> to learn about your rights to seek a recovery. **There is no cost or obligation to participate.**

**WHY LEVI & KORSINSKY:** Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

**CONTACT:**

Levi & Korsinsky, LLP  
Joseph E. Levi, Esq.  
Ed Korsinsky, Esq.  
33 Whitehall Street, 17th Floor  
New York, NY 10004  
[jlevi@levikorsinsky.com](mailto:jlevi@levikorsinsky.com)  
Tel: (212) 363-7500  
Fax: (212) 363-7171  
<https://zlk.com/>

**SOURCE:** Levi & Korsinsky, LLP

### Solutions

Public Companies  
Private Companies  
Agencies  
Legal  
Resellers & Market Research

### Public Relations Products

Access PR Platform  
Press Release Distribution  
Media Database  
Media Pitching  
Media Monitoring  
Media and Industry Targeting

### Investor Relations Products

Access IR Platform  
IR Website  
ADA Compliance  
Earnings Calls  
Earnings Press Releases  
Investor Days

### All Access

All Access  
Conference & Event Software

### Professional Services

Service Plans  
Platform Add-ons

### Blogs

Press Release Topics  
Media Outreach & Engagement Optimization  
Competitor Comparisons  
IR Websites Best Practices  
Earnings Call, Checklists & Preparation  
Earnings Press Release Tips  
Investor Day Recommendations

### Resources

[Press Release Templates](#)  
[Press Release Examples](#)

FAQs

[Product](#)  
[Platform](#)  
[Company](#)

About Us

[Who We Are](#)  
[Meet the Team](#)  
[Investor Relations](#)

Contact Us

+1 888-808-2227  
[Sales](#)  
[Customer Support](#)  
[Editorial](#)  
[Billing Contact](#)

Subscribe to Our Newsletter

Email\*

Press Release Topics

Please Select

protected by reCAPTCHA

Privacy - Terms

Submit